Clinical trial
Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma
NCT00074230 · University Hospital Erlangen, Other · Completed
Key facts
| NCT number | NCT00074230 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma |
| Official title | Vaccination of Stage IV Cutaneous Melanoma Patients With Mature, Autologous Monocyte-Derived Dendritic Cells Transfected With RNAs Encoding for Mage-3, MelanA, and Survivin Antigens |
| Lead sponsor | University Hospital Erlangen, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin |
| Enrollment | 82 |
| Start date | Jul 1, 2003 |
| Primary completion | Mar 1, 2014 |
| Completion | Mar 1, 2014 |
| First posted | Dec 11, 2003 |
| Last update posted | May 12, 2015 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: